Amphista Therapeutics Achieves Breakthrough in Cancer Target Degradation
Amphista Therapeutics, a leader in next-generation targeted protein degradation (TPD), has published a study in Nature Communications demonstrating a novel mechanism for degrading the key cancer target BRD9 using its proprietary Targeted Glue small molecule degrader.
"The deep expertise of our scientists led to the successful integration of the favorable performance characteristics of earlier generation PROTACs and conventional molecular glues but with key limitations designed-out." - Louise Modis, PhD, Chief Scientific Officer at Amphista Therapeutics
The study showcases Amphista's innovative approach to targeted protein degradation, highlighting the potential of its Targeted Glues platform in developing prospectively and rationally designed medicines.
Author's summary: Amphista Therapeutics publishes novel BRD9 degradation mechanism.